Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) The ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

Keytruda is not chemotherapy. It’s a type of treatment called immunotherapy. It works with the body’s immune system, helping T cells fight cancer cells. With immunotherapy, the body’s immune system ...

The FDA has approved Keytruda Qlex, an injected version of a popular cancer drug that until now has only been available via infusion. The FDA approved a new injected version of the cancer ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to be fruitful, as demonstrated through its Keynote-B96 trial in ovarian ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...

Keytruda Qlex (pembrolizumab and berahydaluronidas alfa-pmph) is a prescription drug approved to treat different types of cancer, such as non-small cell lung cancer and head and neck cancer. Keytruda ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial ...

Radiation therapy combined with Keytruda increased T cell infiltration in HR+ and HER2-negative breast cancer, enhancing immune response. High-dose radiation with Keytruda led to increased ...